See What HealthDay Can Do For You
Contact Us

ADA: Genes Affect Control in Type 1 Diabetes

Four variations are linked to high or low blood glucose levels and diabetic complications

MONDAY, June 8 (HealthDay News) -- In patients with type 1 diabetes, four genetic variations are significantly associated with poorer glycemic control, according to research presented at the American Diabetes Association's 69th Scientific Sessions, held from June 5 to 9 in New Orleans.

Andrew D. Paterson, of the Hospital for Sick Children in Toronto, and colleagues analyzed data on more than 1,300 patients enrolled in the National Institutes of Health-sponsored Diabetes Control and Complications Trial, which compared intensive versus conventional control of blood glucose.

The researchers found that one genetic variation -- 10q25.1 (SORCS1) -- reached genome-wide significance in both treatment groups for glycemic control. They also found that two other genetic variations -- 14q32.13 (GSC) and 9p22 (BNC2) -- had close to genome-wide significance in both treatment groups, and that another variation -- 15q21.3 (WDR72) -- had close to genome-wide significance in the intensive-control group. Their analysis also showed that SORCS1 had a significant effect on the rate of hypoglycemia, and that BNC2 was associated with an increased risk of kidney and eye complications.

"Eventually, the genetic variations we found may be used to identify individuals at risk for poor glycemic control and for diabetic complications, so that steps could be taken to intensify control or implement other measures," Paterson said in a statement. "But in the interim, this knowledge may influence the design and analysis of genetic studies attempting to identify risk factors for long-term diabetic complications and lead us in new research directions to better understand the mechanisms of glycemic control."

More Information

Physician's Briefing